Predilife CEO buys again as the June cluster builds

What Ragusa filed, and why it matters

Stéphane Ragusa, Predilife’s chief executive officer, filed a purchase of company shares with the AMF on June 25, 2026. The filing, reference 2026DD1122772, records an approximate value of EUR 25 and our signal score at 48. That is the event. Everything else is interpretation layered on top of a very small trade in a very small company.

The trade sits in a name that was trading at 2.290 EUR on June 26, 2026, according to the market data we could verify. Predilife’s market value was about EUR 9.46 million in the dossier, which puts it squarely in micro-cap territory. That matters because insider buying in a micro-cap is a different animal from the same filing in a large, liquid issuer. The same euro amount can mean very different things. Here, the filing value is tiny in absolute terms, but the context is not tiny at all. The company has been printing a run of buys from the same executive through June, and that is the part worth reading before you decide the EUR 25 is either noise or a signal.

How our score reads the filing

Our scoring put this at 48, which is not a euphoric number and not a dismissal either. The score version in the dossier is V14e, and the drivers are plain enough. First, the filing came from a chief executive, the role our scoring weights most heavily. Second, it was part of an insider cluster, meaning multiple insider trades in the same name within a month. Third, the filing was sized at about 0.00% of the company’s market value, which is a conviction proxy our scoring leans on. Fourth, Predilife sits in the small and mid-cap band where insider information has historically been least priced in. Fifth, the euro-normalised filing value was near EUR 25.

That combination is why the score is middling rather than high. The role is strong. The cluster is supportive. The size is weak. If you are trying to separate a genuine insider read from a ceremonial nibble, the size is the weak link. A CEO buy is always worth more than a random board-level sprinkle, but a EUR 25 filing in a EUR 9.46 million micro-cap is still a very small commitment. It is a signal, not a thesis. Our model treats it that way.

The other thing to keep in view is that the score is not a verdict on the stock. It is a ranking of how much the filing deserves attention. Here, the attention comes from repetition and role, not from size. That distinction matters. A lot of insider commentary gets lazy at exactly this point, turning any CEO buy into a grand statement. This one does not earn that treatment. It earns a closer look because the same executive has been buying repeatedly in June, and because the company is small enough that insider behavior can still matter at the margin.

Predilife’s setup before the filing

Predilife is a Healthcare & Pharma micro-cap with an ISIN of FR0010169920 and ticker ALPRE.PA. The market cap in the dossier is EUR 9,457,205. That is small enough that the company can move on thin liquidity, and it is also small enough that the market often gives management the benefit of the doubt until the business proves itself. That is the backdrop you need before you read any insider buy here.

The public record we could verify around the filing was sparse. No company statement, no analyst note, no contemporaneous news release explaining the trade or a broader buying campaign showed up in the searches we ran. The AMF filing is therefore doing the heavy lifting. That is common in insider work, and it is also why you should resist the urge to over-interpret. In a name this small, silence is not confirmation of anything. It just means the filing is the only hard datapoint on the table.

The price context is equally important. Predilife was at 2.290 EUR on June 26, 2026. Without exact quantity or execution price, we cannot infer the number of shares bought or the percentage ownership change. That is a hard limit, not a nuisance. It means the filing tells us about direction and timing, but not about the precise economic weight of the trade. In a micro-cap, that missing detail matters. A EUR 25 filing can be a token purchase, a compliance-driven transaction, or a tiny add to a larger pattern. The cluster context makes it more interesting, but not magically more informative.

The tape versus the filing

The tape is not giving you a clean confirmation. The most recent share price we could verify was 2.290 EUR on June 26, and there were no other insider filings for Predilife in AMF records or public databases for the seven days ending June 26, 2026, beyond the June cluster already visible in the dossier. That means the market was not being hit with a fresh wave of unrelated disclosures at the same time. The June activity is concentrated in one executive, one name, and a short window.

That concentration cuts both ways. On one hand, repeated buys from the CEO are harder to wave away than a single isolated print. On the other, the absence of a broader insider cohort means this is not a board-wide stampede. It is a one-insider cluster, not a multi-insider chorus. The dossier says there were 10 recent declarations tied to the cluster picture, but only one distinct insider, Stéphane Ragusa. That is a very specific kind of pattern. It can still matter, especially in a micro-cap, but it is not the same as seeing finance, operations, and the board all step in together.

If you are weighing this name, the tape is the part to sit with. The filing value is tiny. The price is low. The company is small. The cluster is real, but narrow. Those facts do not cancel each other out. They tell you that the market is being asked to read a sequence of buys from the person most likely to know the business best, while the public record offers no fresh operational catalyst to anchor the behavior. That is useful, but it is not clean.

What our cohort data says, and what it does not

Insiders Trades cohort data for the PDG/DG micro-cap bucket gives you the historical frame. The sample size is 5,552. The 90-day win rate is 32.4%. The average 90-day return is -5.61%. The average 365-day return is -14.1%. That is the historical record for this role-and-size bucket, not a forecast for Predilife and not a promise that this trade will behave the same way. It is a backward-looking distribution of outcomes, and the distribution is not flattering.

The point of the cohort data is not to talk you out of every buy. It is to stop you from confusing insider activity with easy alpha. A 32.4% win rate at 90 days means the bucket has historically been right less often than wrong, and the negative average returns tell you the losers have outweighed the winners on average. That is the kind of record that should make you more selective, not less alert. When the role is CEO and the company is micro-cap, the signal deserves attention. When the bucket history is this weak, the burden of proof shifts back onto the trade itself.

The dispersion implied by those numbers also matters. A negative average return can coexist with occasional sharp winners, especially in small-cap and micro-cap names where outcomes are lumpy. But the dossier does not give us a clean dispersion table, so we do not pretend otherwise. What we can say is simpler. Historically, this is not a bucket that has rewarded blind following. If you are using Predilife as a test case, the right question is not whether the CEO bought. He did. The right question is whether this particular buy has enough size, repetition, and company context to overcome a weak historical base rate. That is a harder question, and the data says you should treat it as such.

The cluster picture is narrow but persistent

The cluster is the strongest part of the story, and it is also the easiest part to overstate. The dossier flags the filing as part of an insider cluster, and the recent declarations list six June buys by Stéphane Ragusa on June 25, June 18, June 12, June 9, June 9, and June 8. The cluster is therefore not a one-day blip. It is a run of repeated buys over most of the month. That is meaningful because repetition tends to matter more than a single isolated transaction, especially when the same insider keeps showing up.

But the cluster is also narrow. The dossier says there was one distinct insider. So this is not a broad insider accumulation across several executives. It is the CEO, repeatedly. That can be a strong read if you believe the chief executive is the best informed actor in the room, which is often true in a small company. It can also be a sign of conviction that is limited by personal capacity, liquidity, or simple habit. The filing record alone cannot tell you which. It can only tell you that the same name kept buying.

That is why the cluster matters most when paired with the score. Our scoring leaned on the CEO role and the clustering, but it did not ignore the microscopic filing size. That balance is exactly right here. If the buys were larger, the cluster would carry more weight. If the cluster were broader, the same size could be easier to excuse. Instead, you have repeated buys from one executive in a micro-cap, and a score that reflects interest without excess enthusiasm. That is a disciplined read, and it is the one the data supports.

Fundamental health is not available, so do not invent it

The internal dossier does not provide fundamental pillars for Predilife, so there is no transparent screen to walk through here. That absence is itself a fact. It means we cannot dress up the insider buy with a neat list of revenue momentum, margin expansion, balance-sheet strength, or cash burn metrics that were not supplied. In a lot of stories, this is where the copy gets lazy and starts borrowing confidence from a press release. We are not doing that.

What we can say is that the lack of fundamental detail makes the insider read more, not less, important as a piece of evidence. In a micro-cap Healthcare & Pharma name, where the market cap is EUR 9.46 million and the public record around the filing is thin, the trade is one of the few observable actions from inside the company. That does not make it predictive. It makes it relevant. The absence of a fundamental dossier also means the trade should not be mistaken for a valuation argument. A CEO can buy for many reasons, and without the company’s operating metrics in front of us, the filing cannot be converted into a clean fundamental thesis.

So the right discipline is to keep the insider signal in its lane. It tells you that management is still buying into the name in June. It does not tell you whether the business is improving, whether the balance sheet is stable, or whether the next quarter will be better than the last. If you are going to own a micro-cap on insider activity, you need to know which parts of the story you actually have and which parts you are filling in with hope. Here, the dossier gives you the former and not the latter.

Strategy context and what the backtest can, and cannot, claim

Our strategy context is a 90-day holding period with a maximum position size of 0.08. The out-of-sample Sharpe is 0.56 and the out-of-sample CAGR is 17% on a restricted EU venue universe. Those numbers survived a narrow test, but they do not survive search-aware deflation, and the window is short and single-regime. That caveat belongs in the sentence with the numbers, not in a footnote after the fact. The strategy context is useful because it tells you how our system has behaved in a constrained setting. It is not a promise that Predilife will fit the same pattern.

The universe win rate is 51.5%, which is only modestly above a coin flip. That is another reason to stay sober. The strategy is not a magic machine that turns every CEO buy into a trade. It is a filtered framework that has shown some edge in a restricted setting, with clear limits. In a case like Predilife, the framework says the filing is worth attention because the role is high, the cluster is active, and the company is small. It also says the trade size is tiny and the historical bucket is weak. Those two truths sit together.

If you are using this as a live screen, the practical takeaway is simple. The strategy context supports looking, not leaning. It gives you a reason to keep Predilife on the page for another filing or another disclosure. It does not give you a reason to treat a EUR 25 buy as a decisive vote of confidence. That would be too much drama for too little capital at risk.

Risks, caveats, and what to watch next

The first risk is obvious. The filing value is about EUR 25, and that is a very small number in any market. A tiny buy can be a signal, but it can also be a token gesture. Without exact share quantity, execution price, or ownership change, you do not know how much economic weight the transaction carried. That is a real limitation, and it is why the filing should be read as part of a sequence rather than in isolation.

The second risk is historical. The cohort record for PDG/DG micro-cap names is weak, with a 32.4% 90-day win rate, a -5.61% average 90-day return, and a -14.1% average 365-day return. That does not condemn the trade, but it does warn you against overconfidence. The third risk is structural. Predilife is a micro-cap, and micro-caps can be thin, noisy, and vulnerable to narrative drift. A CEO can keep buying while the market does very little with the information.

What to watch is straightforward. Watch for whether Ragusa keeps filing additional buys beyond June 25. Watch for whether another insider joins the pattern, because a broader cluster would change the read. Watch for any company communication that gives the buying a business context, because right now the public record is silent. And watch the share price around 2.290 EUR, not because the price itself proves anything, but because micro-cap insider activity often matters most when it starts to line up with a change in the tape. Until then, this is a CEO who kept buying in June, a weak historical bucket, and a signal that deserves respect without surrendering judgment.

This is not investment advice.